Top

Published in:

01-01-2021 | Acute Promyelocytic Leukemia | Progress in Hematology

Diversity of disseminated intravascular coagulation and selection of appropriate treatments

Author: Hidesaku Asakura

Published in: International Journal of Hematology | Issue 1/2021

Excerpt

Disseminated intravascular coagulation (DIC) represents a serious condition in which systemic and persistent coagulation activation occurs in the presence of an underlying pathology, resulting in the formation of microthrombi in microvessels. Activation of fibrinolysis is observed alongside coagulation, but the degree of fibrinolytic activation varies considerably depending on the underlying diseases. As DIC progresses, hemostatic factors such as platelets and coagulation factors decrease, leading to the pathophysiology of consumption coagulopathy [1]. …

Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341(8):586–92. CrossRef

Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001; 86(5): 1327–30.

Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2(1):20. CrossRef

Harada-Shirado K, Wang X, Mori H, Fukatsu M, Takahashi H, Ikezoe T, et al. Circulating intranuclear proteins may play a role in development of disseminated intravascular coagulation in individuals with acute leukemia. Int J Hematol. 2020;111(3):378–87. CrossRef

Asakura H, Ogawa H. Overcoming bleeding events related to extracorporeal membrane oxygenation in COVID-19. Lancet Respir Med, in press.

Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the research committee on DIC in Japan. Bibl Haematol. 1983;49:265–75.

Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34(3):625–31. CrossRef

Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Wada H, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016;14:42. CrossRef

Wada H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Asakura H, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2017;15:17. CrossRef

10.

Asakura H, Ogawa H. Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC. J Intensive Care. 2020a;8:71. CrossRef

11.

Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5(1):31–41. CrossRef

12.

Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care. 2019;23(1):280. CrossRef

13.

Osone S, Fukushima K, Yano M, Kakazu M, Sano H, Kato Y, et al. Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan. Int J Hematol. 2019;110(6):743–50. CrossRef

14.

Minakata D, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019;109(2):141–6. CrossRef

15.

Asakura H, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost. 2020b;18(6):1521–2. CrossRef

16.

Ogawa H, Asakura H. Consideration of tranexamic acid administration to COVID-19 patients. Physiol Rev. 2020;100(4):1595–6. CrossRef

Title: Diversity of disseminated intravascular coagulation and selection of appropriate treatments
Author: Hidesaku Asakura
Publication date: 01-01-2021
Publisher: Springer Singapore
Keywords: Acute Promyelocytic Leukemia
Aortic Aneurysm
Septicemia
Disseminated Intravascular Coagulation
Septicemia
Fibrinolytic Therapy
Anticoagulant
Aortic Aneurysm
Tranexamic Acid
COVID-19
Heparin
Leukemia
Published in: International Journal of Hematology / Issue 1/2021
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-020-03030-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Recent advances in the research and management of sepsis-associated DIC

Analysis of determinant factors of liver fibrosis progression in ex-thalassemic patients

Ecthyma gangrenosum in an infant with neutropenia

Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis

Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan

Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone

Keynote webinar | Spotlight on antibody–drug conjugates in cancer